Skip to Content
Top of Page: How to talk to a doctor about advanced ovarian cancer >>

Immune globulin intravenous Pregnancy and Breastfeeding Warnings

Immune globulin intravenous is also known as: Bivigam, Carimune, Carimune NF, Flebogamma, Gamimune, Gamimune N 10%, Gamimune N 5%, Gammagard S/D, Gammaplex, Gammar IV, Gammar-P I.V., Gamunex, Iveegam En, Octagam, Panglobulin, Panglobulin NF, Polygam S/D, Privigen, Sandoglobulin, Venoglobulin-S 10%, Venoglobulin-S 5%

Immune globulin intravenous Pregnancy Warnings

Immune globulin intravenous human (IGIV) has been assigned to pregnancy category C by the FDA. Animal studies have not been reported. IGIV has been used successfully during human pregnancy. IGIV is only recommended for use during pregnancy when benefit outweighs risk.

IgG and IgG subclasses have been shown to cross the placenta after 32 weeks of gestation. Placental transfer also appears to be dose and possibly duration dependent. Sacher and colleagues reviewed the clinical indications for IGIV in pregnancy (e.g., hypogammaglobulinemia, immune thrombocytopenic purpura, alloimmune disorders) and recent reports have described the use of IGIV for the prevention of recurrent abortions due to antiphospholipid antibodies, prevention of intracranial hemorrhage in fetal alloimmune thrombocytopenia, neonatal congenital heart block due to maternal antibodies, and severe isoimmunization. No adverse effects have been noted in any of these reports.

See references

Immune globulin intravenous Breastfeeding Warnings

There are no data on the excretion of immune globulin intravenous (human) into human milk.

See references

References for pregnancy information

  1. "Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. Sidiropoulos D, Herrmann U Jr, Morell A, von Muralt G, Barandun S "Transplacental passage of intravenous immunoglobulin in the last trimester of pregnency." J Pediatr 109 (1986): 505-8
  3. Valensise H, Vaquero E, de Carolis C, et al. "Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG)." Prenat Diagn 15 (1995): 509-17
  4. Gounder MP, Baker D, Saletan S, Monheit AG, Hultin MB, Coller BS "Intravenous gammaglobulin therapy in the management of a patient with idiopathic thrombocytopenic purpura and a warm autoimmune erythrocyte panagglutinin during pregnancy." Obstet Gynecol 67 (1986): 741-5
  5. Kaaja R, Julkunen H, Ammala P, Palosuo T, Kurki P "Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies." Acta Obstet Gynecol Scand 72 (1993): 63-6
  6. Sacher RA, King JC "Intravenous gamma-globulin in pregnancy: a review." Obstet Gynecol Surv 44 (1988): 25-34
  7. Spinnato JA, Clark AL, Pierangeli SS, Harris EN "Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy." Am J Obstet Gynecol 172 (1995): 690-4
  8. Bussel JB, Berkowitz RL, McFarland JG, Lynch L, Chitkara U "Antenatal treatment of neonatal alloimmune thrombocytopenia." N Engl J Med 319 (1988): 1374-8
  9. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  10. Clark AL, Gall SA "Clinical uses of intravenous immunoglobulin in pregnancy." Am J Obstet Gynecol 176 (1997): 241-53

References for breastfeeding information

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  2. "Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.